In part, trials evaluating the efficacy of BV together with a combination chemotherapy protocol incorporating cyclophosphamide, doxorubicin and prednisolone (BV-CHP) in CD30+ PTCL (defined as PTCL with >10% CD30 expression) has shown impressive clinical outcomes, particularly championed by the ECHELON-2 landmark trial which boasted a hazard ratio of 0.66 and 0.71 against standard CHOP therapy in terms of OS and PFS respectively, together with a reported 70.1% and 51.4% 5-year OS and PFS (78, 106). Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.